Two Ratios of Propofol-ketamine Admixture for Rapid-sequence Induction Anesthesia for Emergency Laparotomy

Comparison of Different Ratios of Propofol-ketamine Admixture in Rapid-sequence Induction of Anesthesia for Emergency Laparotomy: a Randomized Controlled Trial

Hypotension during anesthesia is associated with serious organ failure and death. The most critical period for intraoperative hypotension is the postinduction period during which, one-third of intraoperative hypotension occurs. Post-induction hypotension has many contributing factors; however, it is closely related to anesthetic drugs. Therefore, manipulation of induction agents makes post-induction hypotension likely preventable. Emergency laparotomy is a critical category of surgery whose patients are usually hemodynamically compromised and prone to post-induction hypotension; furthermore, these patients are usually at high risk of aspiration of gastric contents and require rapid-sequence induction of anesthesia and optimum intubating conditions. Thus, induction of anesthesia for emergency laparotomy requires meticulous balance between achievement of adequate hypnosis and maintenance of stable blood pressure.

Propofol is the commonest hypnotic agent worldwide. However, it is usually associated with hypotension especially in compromised patients. Ketamine produces dissociative anesthesia and sympathetic stimulation which provides more stable hemodynamic profile; however, ketamine is not widely used as a routine hypnotic because it produces psychomimetic effects such as delirium and emergence agitation. Nevertheless, ketamine still has a role in induction of anesthesia in patients with shock and during procedural sedation. Ketamine is also used as analgesic adjuvant during general anesthesia.

Propofol/ketamine admixture (ketofol) was introduced in anesthetic practice aiming to compensate the side effects of the two drugs and to provide, consequently, the desired balance between adequate hypnosis and hemodynamic stability. Ketofol is currently used with a diversity in the ratio between the two drugs which ranges between 1:1 and 1:10 between ketamine and propofol. Despite its frequent use in sedation and complete anesthesia, most of the available literature for comparisons of different ketofol mixtures was restricted to procedural sedation whose results are not applicable in induction of anesthesia due to the different desirable level of hypnosis and recovery. Therefore, the best combination of the two components of ketofol for induction of anesthesia is unknown

Study Overview

• Status: Not yet recruiting
• Conditions: Hypotension; Induction of Anesthesia
• Intervention / Treatment: Drug: Ketofol equal ratio; Drug: Ketofol 1:3 ratio

Detailed Description

Preoperatively, a trained anesthetist will assess the patients regarding the fasting hours, medical history, medications, laboratory investigation, as well as the patient's airway.

In the operating room, routine monitors (electrocardiogram, pulse oximetry, and non-invasive blood pressure monitor) will be applied; intravenous line will be secured, and routine pre-medications (dexamethasone 4 mg as 0.5 mg/ml slow I.V injection) will be administrated. Baseline preoperative blood pressure will be recorded in the supine position as average of 3 readings with difference less than 10% in the systolic blood pressure.

After 3-minutes preoxygenation, patients in the two groups will receive 1 mg/kg lidocaine (in a separate syringe) plus 0.15-0.2 mL/kg from the prepared mixture. This regimen will provide a dose of 1 mg/kg propofol + 1 mg/kg ketamine in the ketofol-1:1 group and 1.5 mg/kg propofol + 0.5 mg/kg ketamine in the ketofol-1:3 group.

Clinical loss of consciousness (defined as no response to auditory command and the disappearance of a patient's eyelash reflex). After loss of consciousness, succinylcholine 1 mg/kg will be administered over 5 seconds, and tracheal intubation will be done through direct laryngoscopy after 60 seconds.

The intubation conditions will be graded by the same anesthetist who performed intubation as excellent, good, or poor for :ease of laryngoscopy, Vocal cord position, Reaction to insertion of the tracheal tube and cuff inflation (Diaphragmatic movement/coughing) Excellent, all criteria excellent; good, all criteria either excellent or good; poor, presence of a single criterion graded as poor.

When the trachea is intubated, mechanical ventilation will be applied to obtain SpO2 > 95% and end-tidal CO2 between 30-40 mmHg and anesthesia will be maintained by isoflurane. Atracurium will be administered after patient recovery from succinylcholine at a dose of 0.5 mg/Kg. Atracurium increments of 10 mg will be administered every 20 min for maintenance of muscle relaxation.

Any episode of hypotension (defined as mean arterial pressure [MAP] <70 mmHg) will be managed by 5 mcg norepinephrine (which will be repeated if hypotension persists for 2 minutes).

If hypertension or tachycardia occurred (defined as MAP or heart rate >120% of baseline), it will be managed by IV 0.5 mg/kg propofol.

After skin incision, hemodynamic and anesthetic management will be according to the attending anesthetist discretion.

• Study Type: Interventional
• Enrollment (Anticipated): 74
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: ahmed hasanin, M.D; Phone Number: +2 01095076954; Email: ahmedmohamedhasanin@gmail.com

Study Locations

• Egypt
  • Cairo, Egypt, 11562
    • Kasr Alaini hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• adult patients (18-65 years),
• American society of anesthesiologist I-III,
• scheduled for emergency laparotomy under general anesthesia

Exclusion Criteria:

• history of difficult intubation,
• abnormal airway examination,
• cardiac morbidities (impaired contractility with ejection fraction < 50%, heart block, arrhythmias, tight valvular lesions),
• patients on angiotensin converting enzyme inhibitors and angiotensin receptor blockers medications,
• patients with uncontrolled hypertension,
• patient with allergy of any of the study drugs
• Patients on vasopressor infusion,
• patients with high shock index (heart rate / systolic blood pressure >1),
• body mass index > 35 kg/m2, increased intracranial tension
• pregnant women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: ketofol 1:1; 0.15-0.2 mL/kg from of 5 mg/mL propofol and 5 mg/mL ketamine mixture	Drug: Ketofol equal ratio; 5mg/ml10 mL propofol (100 mg) will be mixed with 2 mL ketamine (100 mg) and then diluted to a total volume of 20 mL to have a final concentration of 5 mg/mL propofol and 5 mg/mL ketamine
Active Comparator: ketofol 1:3; 0.15-0.2 mL/kg from of 7.5 mg/mL propofol and 2.5 mg/mL ketamine mixture	Drug: Ketofol 1:3 ratio; 15 mL propofol (150 mg) will be mixed with 1 mL ketamine (50 mg) and then diluted to a total volume of 20 mL to have a final concentration of 7.5 mg/mL propofol and 2.5 mg/mL ketamine).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
norepinephrine dose	microgram	1 minute after induction of anesthesia until 15-minutes after induction

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
postinduction hypotension	mean arterial pressure <70 mmHg	1 minute after induction of anesthesia until 15-minutes after induction
severe postinduction hypotension	mean arterial pressure <60 mmHg	1 minute after induction of anesthesia until 15-minutes after induction
postinduction hypertension	mean arterial pressure >120% baseline	1 minute after induction of anesthesia until 15-minutes after induction
intubation condition	*Excellent, all criteria excellent; good, all criteria either excellent or good; poor, presence of a single criterion graded as poor; Ease of laryngoscopy Excellent: Easy: jaw relaxed, no resistance to blade insertion Good : Fair: jaw not fully relaxed, slight resistance to blade insertion Poor: Difficult: poor jaw relaxation, active resistance of the patient to laryngoscopy; Vocal cord position Excellent: Abducted Good : Intermediate/moving Poor: Closed; Reaction to insertion of the tracheal tube and cuff inflation (Diaphragmatic movement/coughing) Excellent: None Good: Diaphragm/slight: One to two weak contractions or movement for less than 5 s. Poor: Sustained/ Vigorous: More than two contractions and/or movement for longer than 5 s.	60 seconds after induction of anesthesia to 180 seconds after induction
total propofol dose	mg	0 second after induction of anesthesia to 180 seconds after induction

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
mean arterial pressure	mmHg	1-minte before the induction, immediately after induction, immediately after intubation, then every 2-minutes for 15-minutes after induction
heart rate	beat per minute	1-minte before the induction, immediately after induction, immediately after intubation, then every 2-minutes for 15-minutes after induction

Collaborators and Investigators

• Sponsor: Kasr El Aini Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2021
• Primary Completion (Anticipated): March 1, 2022
• Study Completion (Anticipated): March 1, 2022

Study Registration Dates

• First Submitted: November 24, 2021
• First Submitted That Met QC Criteria: December 8, 2021
• First Posted (Actual): December 21, 2021

Study Record Updates

• Last Update Posted (Actual): December 21, 2021
• Last Update Submitted That Met QC Criteria: December 8, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Disease Attributes; Emergencies; Hypotension
• Other Study ID Numbers: MS-450-2021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: will be provided upon reasonable request

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No